Investment Objective
The investment seeks investment results that, before fees and expenses, correspond generally to the total return performance of an index that tracks the health care sector of developed global markets outside the United States.
The fund employs a sampling strategy in seeking to track the performance of the S&P Developed Ex-U.S. BMI Health Care Sector Index. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index or in American Depositary Receipts ("ADRs") or Global Depositary Receipts ("GDRs") based on securities comprising the index.
Latest IRY News
No recent news for SPDR S&P International Health Care Sector ETF.
Performance
| 1 month | +2.99% | | 3 years | +19.54% |
| 3 months | +8.63% | | 5 years | -- |
| 1 year | +36.97% | | Since inception | +8.32% |
Quote Details
| Previous close | $41.45 |
| Open day’s range | 41.24 – 41.73 |
| Net asset value (NAV) | 41.26 (05/20/2013) |
| Daily volume | 114,652 |
| Average volume (3 months) | 18,547 |
Data as of 4:00pm ET, 05/21/2013
Peer Comparisonvs. Health ETFs
| | IRY | Category |
|---|
| Performance 5-yr return | -- | +13.03% |
| Expense Gross exp ratio | 0.50% | 0.47% |
| Risk 5 year sharpe ratio | -- | 0.75 |
| Net assets | $51.8M | $776.1M |
| Average market cap | $41.4B | $19.4B |
| Average P/E | 22.3 | 21.6 |
| Dividend / Share | -- | 0.22% |
Competitors
| VHT Vanguard Health Care ETF |
| XLV Health Care Select Sector SPDR Fund |
| IXJ iShares S&P Global Healthcare Index Fund |
Holdings
Top 5 Sectors
Portfolio weighting
Top 10 Holdings
Portfolio weighting
| -- Novartis AG | 11.57% |
| -- Roche Holding AG | 10.45% |
| -- Sanofi | 7.58% |
| -- GlaxoSmithKline PLC | 7.40% |
| -- Bayer AG | 4.97% |
| -- Novo Nordisk A/S | 4.41% |
| -- AstraZeneca PLC | 4.34% |
| -- Takeda Pharmaceutical Co., Ltd. | 3.36% |
| -- Teva Pharmaceutical Industries Ltd | 3.02% |
| -- CSL Limited | 2.72% |
+0.23 / +0.55%
-0.78 / -1.87%
.
